Free Republic
Browse · Search
General/Chat
Topics · Post Article

Skip to comments.

New Antibiotic Ceftobiprole Shows Promise Against Resistant Staph Infections
UPI ^ | SEPT. 28, 2023 | Cara Murez

Posted on 09/29/2023 6:30:56 PM PDT by nickcarraway

New research shows that an antibiotic effective for bacterial pneumonia also appears to fight treatment-resistant staph infections.

The drug is ceftobiprole. It appeared successful in fighting methicillin-resistant staph infections, sometimes called MRSA. It showed similar benefit when tested against the antibiotic daptomycin to treat complicated Staphylococcus aureus infections.

This means it could offer another option against this common and often deadly bacterial infection, according to the research led by Duke Health in Durham, N.C.

"This is an area of true need," Dr. Thomas Holland, associate professor at Duke University School of Medicine and chair of the study's data review committee, said in a Duke Health news release. "There has not been a new antibiotic approved for the treatment of S. aureus bacteremia for over 15 years."

The researchers studied the antibiotics in 390 patients in 17 countries who had complicated staph infections between 2018 and 2022. Roughly half were randomly assigned to receive infusions of ceftobiprole. The other half were treated intravenously with daptomycin.

The investigators assessed safety and overall treatment success, measured as survival, clearance of bacteria from the bloodstream, symptom improvement and no new bacterial complications 70 days after treatment.

Both antibiotics performed similarly.

In the ceftobiprole group, 69.8% of patients experienced overall success. That was compared to 68.7% in the daptomycin group. Gastrointestinal issues were the most common side effect for both drugs.

"Despite a lot of work in medical science, complicated staph infections still have a 25% [death] rate at 90 days," said study co-author Dr. Vance Fowler, a professor of medicine and molecular genetics and microbiology at Duke. "We need more options for treating these infections."

The study was sponsored by Basilea Pharmaceutica International Ltd., which markets ceftobiprole.

The findings were published online Wednesday in the New England Journal of Medicine.


TOPICS: Business/Economy; Health/Medicine
KEYWORDS: antibiotic; infections; staph

1 posted on 09/29/2023 6:30:56 PM PDT by nickcarraway
[ Post Reply | Private Reply | View Replies]

To: nickcarraway

Good to hear. Other than Democrats in control of our nuclear weapons, NOTHING scares me more than a microbe finally being resistant to all antibiotics.


2 posted on 09/29/2023 6:34:16 PM PDT by BobL (I own an F150 so that I can tow my boat all day Saturday and look Manly)
[ Post Reply | Private Reply | To 1 | View Replies]

To: nickcarraway

BTTT!


3 posted on 09/29/2023 7:50:41 PM PDT by Salvation ("With God all things are possible." Matthew 19:26)
[ Post Reply | Private Reply | To 1 | View Replies]

Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.

Free Republic
Browse · Search
General/Chat
Topics · Post Article

FreeRepublic, LLC, PO BOX 9771, FRESNO, CA 93794
FreeRepublic.com is powered by software copyright 2000-2008 John Robinson